Pyrazolidine-3,5-diones and 5-hydroxy-1H-pyrazol-3(2H)-ones, inhibitors of UDP-N-acetylenolpyruvyl glucosamine reductases

Journal of Medicinal Chemistry

Volumn 49, Issue 20, 2006, Pages 6027-6036

  Gilbert, Adam M ^a   Failli, Amedeo ^b   Shumsky, Jay ^b   Yang, Youjun ^a,c   Severin, Anatoly ^a   Singh, Guy ^a   Hu, William ^a   Keeney, David ^a   Petersen, Peter J ^a   Katz, Alan H ^b  

^a Wyeth   (United States)

^b Chemical Sciences   (United States)

^c Avon Products Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXY 1H PYRAZOL 3(2H) ONE DERIVATIVE; OXIDOREDUCTASE INHIBITOR; PYRAZOLIDINE 3,5 DIONE DERIVATIVE; PYRAZOLONE DERIVATIVE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE N ACETYLENOLPYRUVYL GLUCOSAMINE REDUCTASE INHIBITOR;

ANTIMICROBIAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; LIPOPHILICITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; CANDIDA ALBICANS; CARBOHYDRATE DEHYDROGENASES; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; PEPTIDOGLYCAN; PYRAZOLES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33749265829     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060499t     Document Type: Article

References (28)

1. Bronson, J. J.; Barrett, J. F. Recent developments in antibacterial research. Annu. Rep. Med. Chem. 2001, 36, 89-98.
2. Benson, T. E.; Marquardt, J. L.; Marquardt, A. C.; Etzkorn, F. A.; Walsh, C. T. Overexpression, purification, and mechanistic study of UDP-N-acetylenolpyruvylglucosamine reductase. Biochemistry 1993, 32 (8), 2024-30.
3. Benson, T. E.; Filman, D. J.; Walsh, C. T.; Hogle, J. M. An enzyme-substrate complex involved in bacterial cell wall biosynthesis. Nat. Struct. Biol. 1995, 2 (8), 644-53.
4. Benson, T. E.; Walsh, C. T.; Massey, V. Kinetic characterization of wild-type and S229A mutant MurB: Evidence for the role of Ser 229 as a general acid. Biochemistry 1997, 36 (4), 796-805.
5. Lees, W. J.; Benson, T. E.; Hogle, J. M.; Walsh, C. T. (E)-enolbutyryl-UDP-N-acetylglucosamine as a mechanistic probe of UDP-N-acetylenolpyruvylglucosamine reductase (MurB). Biochemistry 1996, 35 (5), 1342-51.
6. Benson, T. E.; Harris, M. S.; Choi, G. H.; Cialdella, J. I.; Herberg, J. T.; Martin, J. P., Jr.; Baldwin, E. T. A structural variation for MurB: X-ray crystal structure of Staphylococcus aureus UDP-N-acetylenolpyruvylglucosamine reductase (MurB). Biochemistry 2001, 40 (8), 2340-50.
7. Francisco, G. D.; Li, Z.; Albright, J. D.; Eudy, N. H.; Katz, A. H.; Petersen, P. J.; Labthavikul, P.; Singh, G.; Yang, Y.; Rasmussen, B. A.; Lin, Y. I.; Mansour, T. S. Phenyl thiazolyl urea and carbamate derivatives as new inhibitors of bacterial cell-wall biosynthesis. Bioorg. Med. Chem. Lett. 2004, 14(1), 235-8.
8. Li, Z.; Francisco, G. D.; Hu, W.; Labthavikul, P.; Petersen, P. J.; Severin, A.; Singh, G.; Yang, Y.; Rasmussen, B. A.; Lin, Y. I.; Skotnicki, J. S.; Mansour, T. S. 2-Phenyl-5,6-dihydro-2H-thieno[3,2-c]pyrazol-3-ol derivatives as new inhibitors of bacterial cell wall biosynthesis. Bioorg. Med. Chem. Lett. 2003, 13 (15), 2591-4.
9. Bronson, J. J.; DenBleyker, K. L.; Falk, P. J.; Mate, R. A.; Ho, H. T.; Pucci, M. J.; Snyder, L. B. Discovery of the first antibacterial small molecule inhibitors of MurB. Bioorg. Med. Chem. Lett. 2003, 13 (5), 873-5.
10. Antane, S.; Caufield, C. E.; Hu, W.; Keeney, D.; Labthavikul, P.; Morris, K.; Naughton, S. M.; Petersen, P. J.; Rasmussen, B. A.; Singh, G.; Yang, Y. Pulvinones as bacterial cell wall biosynthesis inhibitors. Bioorg. Med. Chem. Lett. 2006, 16(1), 176-80.
11. Kutterer, K. M.; Davis, J. M.; Singh, G.; Yang, Y.; Hu, W.; Severin, A.; Rasmussen, B. A.; Krishnamurthy, G.; Failli, A.; Katz, A. H. 4-Alkyl and 4,4′-dialkyl 1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione derivatives as new inhibitors of bacterial cell wall biosynthesis. Bioorg. Med. Chem. Lett. 2005, 15 (10), 2527-31.
12. Yang, Y.; Severin, A.; Chopra, R.; Krishnamurthy, G.; Singh, G.; Hu, W.; Keeney, D.; Svenson, K.; Petersen, P. J.; Labthavikul, P.; Shlaes, D. M.; Rasmussen, B. A.; Failli, A. A.; Shumsky, J. S.; Kutterer, K. M.; Gilbert, A.; Mansour, T. S. 3,5-dioxopyrazolidines, novel inhibitors of UDP-N- acetylenolpyruvylglucosamine reductase (MurB) with activity against gram-positive bacteria. Antimicrob. Agents Chemother. 2006, 50 (2), 556-64.
13. Shine, H. J.; Rhee, E. S. The preparation of 4,4′- dichloroazobenzene-15N,15N′ and -4,4′-13C2 and 4-chloroazobenzene- 15N,15N′. J. Labelled Compd. Radiopharm. 1984, 21 (6), 569-73.
14. Shine, H. J.; Trisler, J. C. Thermal rearrangement of hydrazo compounds. III. The kinetics and mechanism of the rearrangement of 2,2′- hydrazonaphthalene in polar solvents. J. Am. Chem. Soc. 1960, 82 (15), 4054-8.
15. 4-Substituted 1,2-diaryl-3,5-dioxopyrazolidines. US Patent 921467, 1963.
16. Logemann, W.; Lauria, F.; Zamboni, V. Friedel-Crafts and Mannich reactions with 3,5-dioxo-1,2-diphenylpyrazolidine. Chem. Ber. 1955, 88, 1353-60.
17. Dhalla, A. M.; Yanchunas, J., Jr.; Ho, H. T.; Falk, P. J.; Villafranca, J. J.; Robertson, J. G. Steady-state kinetic mechanism of Escherichia coli UDP-N-acetylenolpyruvylglucosamine reductase. Biochemistry 1995, 34, (16), 5390-402.
18. Merrikin, D. J.; Briant, J.; Rolinson, G. N. Effect of protein binding on antibiotic activity in vivo. J. Antimicrob. Chemother. 1983, 11 (3), 233-8.
19. Staahle, L.; Wold, S. Partial least-squares analysis with cross-validation for the two-class problem: A Monte Carlo study. J. Chemometr. 1987, 1 (3), 185-96.
20. Eriksson, L.; Johnasson, E.; Kettaneh-Wold, N.; Wold, S. Introduction to Multi- and Megavariate Data Analysis using Projection Methods (PCA & PLS); Umetrics AB: Umea, Sweden, 1999.
21. Umetrics. SIMCA-P, 11.0; 2005.
22. Xu, W. Unpublished results.
23. Joseph-McCarthy, D.; Thomas, B. E. t.; Belmarsh, M.; Moustakas, D.; Alvarez, J. C. Pharmacophore-based molecular docking to account for ligand flexibility. Proteins 2003, 51 (2), 172-88.
24. McMartin, C.; Bohacek, R. S. QXP: Powerful, rapid computer algorithms for structure-based drug design. J. Comput. Aided Mol. Des. 1997, 11 (4), 333-44.
25. Benson, T. E.; Walsh, C. T.; Hogle, J. M. X-ray crystal structures of the S229A mutant and wild-type MurB in the presence of the substrate enolpyruvyl-UDP-N-acetylglucosamine at 1.8-Å resolution. Biochemistry 1997, 36 (4), 806-11.
26. Sampson, B. A.; Misra, R.; Benson, S. A. Identification and characterization of a new gene of Escherichia coli K-12 involved in outer membrane permeability. Genetics 1989, 122 (3), 491-501.
27. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: Approved standard M7-A5; National Committee for Clinical Laboratory Standards: Wayne, PA, 2000.
28. Boothby, D.; Daneo-Moore, L.; Shockman, G. D. A rapid, quantitative, and selective estimation of radioactively labeled peptidoglycan in Gram-positive bacteria. Anal. Biochem. 1971, 44 (2), 645-53.